Objective-Scavenger receptor A (SR-A) is abundantly expressed by macrophage and plays a critical role in foam cell formation and atherogenesis. In search of selective SR-AI antagonists, we have used affinity selection of a phage displayed peptide library on the synthetic extracellular domain of SR-AI. Methods and Results-Phage selection led to an almost 1,000-fold enrichment of SR-AI binding phage, which bound avidly to human THP-1 cells. A 15-mer corresponding to the peptide insert of the major SR-AI binding phage (PP1) displaced phage binding to SR-AI. Peptides, docked to a streptavidin scaffold, were effectively internalized by macrophages in an SR-AI-dependent manner. The enriched phage pool and streptavidin bound PP1 exhibited marked uptake by hepatic macrophages in mice. Importantly, PP1 significantly increased streptavidin as well as particulate accumulation in advanced aortic plaques, and in particular intraplaque macrophage, of apolipoprotein E Ϫ/Ϫ mice.
M acrophages play a key role in atherosclerosis at all stages of disease development. 1 They express a range of scavenger receptors, such as scavenger receptor A (SR-A), [2] [3] [4] [5] the driving actors in foam cell formation. SR-A is a trimeric transmembrane glycoprotein consisting of 6 distinct domains 2, 6 and can exist in 1 of 3 isoforms (SR-AI, SR-AII, and SR-AIII). 7, 8 As a pattern recognition receptor, it displays a very broad substrate profile, internalizing modified low-density lipoprotein, polynucleotides (eg, polyinosinic and polyguanylic acid), polysaccharides (eg, fucoidan), and lipopolysaccharides. [9] [10] [11] SR-A was found to be abundantly expressed by macrophages, foam cells, and smooth muscle cells 12 in atherosclerotic lesions but not in the normal vessel wall. 13, 14 A causal role of SR-A in atherogenesis was first established by Suzuki et al, 4 showing reduced lesion formation in SR-A-deficient apolipoprotein E (ApoE) Ϫ/Ϫ , a notion confirmed in further studies. 15 The marked expression of SR-AI by macrophages in plaques-especially vulnerable plaques-and the efficient endocytosis of its substrates by SR-AI render it not only an interesting candidate for therapeutic intervention in atherosclerosis but also for targeted drug delivery and imaging approaches. 16 Application of selective SR-AI ligands as homing device for contrast agents may therefore allow molecular imaging of atherosclerotic plaques in general but also give insight into their actual composition and stability. Illustrative, macrophagetargeted molecular magnetic resonance imaging of atherosclerotic plaques has already been shown for immunomicelles equipped with antibodies for macrophage scavenger receptor 17 or for oxidation specific epitopes. 18 The bulky and chemically complex nature of its macromolecular substrates make ligand design for SR-AI rather unsuccessful, and only a single report was published on a synthetic, moderately selective SR-A antagonist. 19 In this study, we describe the unbiased design of SR-AI antagonists involving the use of phage display on a synthetic receptor comprising the actual ligand-binding pocket of SR-AI. A selective peptide antagonist for SR-AI was identified, which constitutes a promising lead to the development of SR-AI targeted therapy and imaging of atherosclerotic lesions.
Materials and Methods
Detailed information regarding materials and methods is given in the online-only Data Supplement.
Scavenger Receptor Gene Expression Levels
Female ApoE Ϫ/Ϫ mice (back-crossed for 9 generations on a C57Bl/6 background) and C57Bl/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and Broekman (Someren, the Netherlands), respectively. After whole-body perfusion, aortic arches were excised, and RNA isolation, cDNA synthesis, and expression analysis were performed as described earlier. 20
Peptide Selection via Phage Display
The pComb8 phage-displayed peptide library CX 15 C (in which X is any amino acid and C is a fixed cysteine residue) was generated by Dr Pannekoek (Amsterdam, the Netherlands), and pIF4 phage libraries were kindly provided by Dr P. Monaci (Rome, Italy). 21, 22 Selection of the both libraries was performed on immobilized SR-AI for 7 rounds of selection. After each selection round phage were titrated, amplified, and purified as described. 23 Amplified phage was used for further selection. Enriched phage pools underwent DNA sequencing using a standard M13 primer. Unless otherwise stated, the amplified phage pool of round 7 was used for further characterization experiments.
Peptide Synthesis
All peptides were synthesized on an automated peptide synthesizer (9050 Millipore) using standard Fmoc solid-phase peptide synthesis. Crude peptides were purified on a preparative C 8 reverse phasehigh-performance liquid chromatography column (Altech, Deerfield, IL) using a JASCO PU-980 (Tokyo, Japan). The purity of all peptides used for the truncation assay as assessed by matrix-assisted laser desorption ionization/time of flight mass spectrometry, and C 18 reverse phase-high-performance liquid chromatography was Ͼ70%, whereas PP1 and biotinylated PP1 (LSLERFLRCWSDAPAKbiotin; BioPP1), used for all subsequent in vitro and in vivo studies, had a purity of Ͼ95%. Synthetic biotinylated bovine SR-AI was synthesized, purified, and characterized as described by Suzuki et al. 24 
Competition Experiment of SR-AI-Selected Phage Pool
In analogy to the phage selection conditions, immobilized SR-AI was incubated with SR-AI ligands or synthetic SR-AI peptides (full-length or N-terminal truncations of 7, 9, 11, and 13 amino acids) and with the enriched phage pool (round 7) at 10 9 colonyforming unit. Residual phage binding was calculated from the output-to-input ratio (the ratio between titers of acid-eluted phage (output) and the actual input (generally 10 9 -10 10 colony-forming unit), as determined by the conventional phage titer assay.
Cell Culture and In Vitro Studies
Murine macrophage cells (RAW264.7), African green monkey kidney COS-7 and human monocytic THP-1 cells were grown in complete Dulbecco's modified Eagle's medium.
For the binding assay, cells were incubated with SR-AI specific phage (round 7), and nonselected phage library was used as a negative control. Input samples were taken from the incubation medium immediately after addition of the phage and output samples from the cell lysate. The recovery of bound phage was calculated from the output-to-input ratio.
Displacement studies of PP1 binding, were performed on RAW264.7 cells incubated with 125 I-strep-bioPP1 in the presence of fucoidan (Sigma-Aldrich, St. Louis, MO) at the indicated concentrations. Radioactivity of cell lysates was measured in a ␥-counter.
PP1 Peptide Binding to Macrophage SR-AI
Bone marrow-derived macrophages were isolated from C57Bl/6 mice and cultured as described before. 25 Mature bone marrow-derived macrophages were incubated with 0.38 mol/L of streptavidin-R-phycoerythrin (PE) (strepPE), strepPE-bioPP1 or strepPE-bioPP1 premixed with fucoidan. After incubation with 4=,6-diamidino-2phenylindole (Molecular Probes), cytospins (300 rpm, 5 minutes) were analyzed with fluorescence microscopy. Similarly, cells were incubated with fluorescein isothiocyanate-labeled F4/80 antibody (Immunosource, Zoersel, Belgium) and analyzed by flow cytometric analysis (fluorescence-activated cell sorting).
In Vivo Organ Distribution Studies of Phage and Peptide
SR-AI-specific PP1 phage and a nonselected control phage were radiolabeled 23 and injected intravenously at 10 9 colony-forming unit in C57Bl/6 mice (20-week-old male mice; Nϭ6). The parental phage library served as control phage. After 30 minutes, organs were analyzed for 35 S radioactivity in a ␤-counter (PerkinElmer, Boston, MA). 125 I-Strep-biotin or 125 I-strep-bioPP1 (0.38 mol/L) was intravenously injected in C57Bl/6 mice (Nϭ6; male, 20 weeks). Radioactivity in serum samples and organs was analyzed in a Wizard 1470 automated ␥-radiation counter (PerkinElmer).
In Vivo Colocalization of PP1 Uptake With Tissue Resident Macrophages
Biotinylated PP1 docked on strepPE at 5:1 ratio (online-only Data Supplement) was injected intravenously (0.38 mol/L) into C57Bl/6 and CD36 Ϫ/Ϫ /SR-A Ϫ/Ϫ mice (Nϭ2). Biotin docked strepPE was used as a control. Immunostaining of liver and spleen was performed using a F4/80 monoclonal mouse antibody (1:100, BMA Biomedicals, Augst, Switzerland), an Alexa 488 -labeled goat anti-rat secondary antibody (1:50, Molecular Probes Inc, Eugene, OR) and nuclear 4=,6-diamidino-2-phenylindole staining. Slides were analyzed on a Bio-Rad Radiance 2100 MP confocal laser scanning system equipped with a Nikon Eclipse TE2000-U inverted fluorescence microscope.
Plaque Uptake and Intraplaque Macrophage Colocalization of PP1
Aged ApoE Ϫ/Ϫ mice (Ͼ65 weeks, male, chow diet) with advanced atherosclerotic lesions were injected intravenously with 125 I-strepbiotin or 125 I-strep-bioPP1 (0.38 mol/L, Nϭ3). In a similar experiment, aged ApoE Ϫ/Ϫ mice were injected intravenously with control or PP1-conjugated Quantumdot Nanocrystals (0.38 mol/L; Nϭ4 -5) (Invitrogen, Breda, the Netherlands). Aortic valve area and aortas were isolated. Radiolabeled aortas were subjected to en face autoradiographic analysis, whereas the accumulated en face aortic Qdot signal was analyzed with an IVIS Lumina Imaging System (Xenogen, Almeda, CA). Autoradiograph signal intensity was computationally quantified by ImageQuant Software. Qdot signal intensity was quantified by Living Image software (Xenogen). Results are expressed as normalized enhancement ratio compared with the nontargeted control and corrected for lesion area as determined with an Oil Red O staining (manufacturers protocol) of the aortas. Lesion-prone aortic valve area with Qdot signal were stained for F4/80 as described earlier; F4/80 staining and Qdot crystal accumulation were visualized by fluorescence microscopy.
Statistical Analysis and Animal Handling Ethics
C57Bl/6 mice were obtained from Charles River Laboratories (Maastricht, the Netherlands). ApoE Ϫ/Ϫ and SR-AI Ϫ/Ϫ /CD36 Ϫ/Ϫ mice were obtained from the local animal breeding facility (Leiden, the Netherlands). All animal work was approved by the regulatory authorities of Leiden and complied with the Dutch government guidelines. Values are expressed as meanϮSEM. A 2-tailed unpaired Student t test was used to compare individual groups. PϽ0.05 levels were considered significant.
Results

SR-AI as a Target for Molecular Plaque Imaging
Aortic arch gene expression levels of SR-AI and SR-BI in ApoE Ϫ/Ϫ mice revealed enhanced expression of SR-BI only at 10 to 12 weeks of age, when initial lesions have formed; SR-AI expression progressively increased from week 12 until week 40 ( Figure 1A) . As previously been shown by 't Hoen et al, 20 the SR-AI expression pattern paralleled the increase in lesion size and in intraplaque macrophages, as reflected by CD68-expression. These data essentially confirm SR-AI as an interesting candidate for molecular targeting of advanced atherosclerosis.
Therefore, we set out to screen a 15-mer phage displayed peptide library for SR-AI binding peptide ligands. To favor the selection of peptides binding to the actual binding pocket of SR-AI, biopanning was performed on wells coated with a streptavidin associated, biotinylated peptide scaffold encompassing the complete ligand binding motif of SR-AI. 24 In the first 2 rounds, a nonstringent washing protocol with ice-cold binding buffer was used, whereas from round 3 onward stringency was gradually increased by decreasing the coating density of synthetic SR-AI and by using a binding buffer of room temperature for washing. This led to a significant enrichment of binding phage in the fifth round, culminating in an almost 1,000-fold increase after 7 rounds of biopanning ( Figure 1B ). Subsequent DNA sequence analysis of 10 phage clones from the sixth and seventh selection rounds revealed a 12-mer consensus motif. Eight of 10 phage clones from round 6 shared the peptide sequence LSLERFLRCWSDAPA (PP1), and 2 of 10 clones carried a highly homologous LSLERFLRCWSDSPR (PP2) insert. In the seventh round, only PP1 clones were detected, suggesting that PP1 phage was more effectively bound than PP2. Compared with the parental nonselected phage library, the enriched phage pool showed high binding to streptavidin immobilized SR-AI but only marginal binding to streptavidin immobilized biotin or to type-2 collagen S. There was no binding of the control phage to streptavidin immobilized SR-AI, confirming that binding of the selected phage pool implicated the SR-AI moiety ( Figure 1C ).
Cell Binding of the Enriched Phage Pool
To verify whether the selected phage pool (PP1) was also able to bind to the full-length receptor on macrophages, we have tested the ability of the phage pool binding to human THP-1 and murine RAW264.7 cells, which both were shown to display SR-AI expression. Compared with the parental phage library, the selected phage avidly bound to THP-1 ( Figure  1D ) and to a lesser extent to RAW264.7 cells. Binding to the latter was Ͼ2-fold higher than that to monkey COS-7 cells, which are deficient in SR-AI.
Competition Assay of Phage Binding to SR-AI by Established SR-AI Inhibitors
To further characterize the specificity and affinity of the selected phage binding, displacement studies of phage binding to synthetic SR-AI by the established SR-AI inhibitors polyinosinic acid (poly-I) and succinylated human serum albumin were performed. Both poly-I and succinylated human serum albumin were able to dose-dependently compete for phage binding to SR-AI at IC 50 values of 10.5 and 66 g/mL, respectively ( Figure IA 
Competition Assay of Phage Binding to SR-AI by Synthetic Peptides
DNA sequence analysis revealed the presence of a 12-mer consensus sequence within the peptide insert of the PP1/ PP2 phage clones, suggesting that the N-terminal part of the phage encoded peptide is instrumental in SR-AI binding. To pinpoint the minimal peptide sequence required for SR-AI binding, we performed a truncation study, focusing mainly on the N terminus of the peptide. Full-length peptide LSLERFLRCWSDAPA (PP1) and truncated peptides LERFLRCWSDAPA (PP1-13), RFLRCWSDAPA (PP1-11), LRCWSDAPA (PP1-9), and CWSDAPA (PP1-7) were synthesized by Fmoc chemistry. The capacity of the peptides to interfere with phage binding to SR-AI was tested in a competition assay, at which residual binding of the selected phage to SR-AI was determined in the presence of the synthetic peptides ( Figure 1E ). PP1 could dose-dependently and potently inhibit SR-AI binding of the enriched phage at an IC 50 value of 29 mol/L. Stepwise truncation of PP1 resulted in a gradual loss in affinity, and the 11-mer peptide PP1-11 was identified as the minimal motif of PP1 to be able to avidly bind SR-AI.
PP1 Peptide Selectively Binds In Vitro to Macrophage in an SR-AI-Dependent Manner
We have incubated streptavidin with different molar ratio of biotinylated PP1 peptide to prepare tetrameric strep-bioPP1 complexes. Sephadex gel chromatography revealed that a protein to peptide ratio of 1:5 was optimal for conjugation and led to occupation of most of the biotin binding sites on streptavidin ( Figure IB (Figure 2A ).
To illustrate that strep-bioPP1 selectively binds to macrophages in an SR-AI-dependent rather than nonspecific manner, the binding of streptavidin-PE-conjugated PP1 peptide to macrophages was investigated by immunocytochemistry. Bone marrow-derived macrophages were cultured in conditioned medium containing macrophage colony-stimulating factor, to induce differentiation of progenitors into functional macrophages with SR-AI expression. Fluorescence-activated cell sorting analysis was used to confirm the macrophage population (F4/80-positive Ͼ99%, data not shown). When conjugated to the streptavidin scaffold, PP1 was able to confer significant uptake signal at concentrations as low as 40 nmol/L. Furthermore, unlike strepPE-biotin, strepPE-bioPP1 specifically accumulated in macrophages ( Figure 2C ). StrepPE-bioPP1 localized both at the membrane and in the cytosol, suggesting that PP1 uptake had occurred through receptor mediated rather than adsorptive endocytosis. Binding and internalization of strepPE-bioPP1 was abrogated by pretreatment with 1 mg/mL fucoidan, establishing once more underpinning the selectivity of PP1 for SR-AI. These findings could be verified quantitatively by flow cytometric analysis, in that the mean PE-derived fluorescent intensity within the F4/80 ϩ macrophage population was more than 8-fold increased after PP1 targeting compared with its nontargeted counterpart. Similar to the above experiment, PP1-targeted uptake could largely be inhibited by preincubation with an SR-AI inhibitor, fucoidan, firmly establishing the involvement of SR-AI in PP1 targeting ( Figure 2B ).
Selective Uptake of SR-AI Binding Phage and Phage-Encoded Peptide In Vivo
As SR-AI is expressed mainly by resident macrophages in various organs, including liver, 26 we have examined the capacity of PP1 phage and PP1 peptide to accumulate in the liver after intravenous injection into C57Bl/6 mice. The PP1 phage displayed a significant 2-fold increase in liver accumulation compared with control phage. Liver and spleen appeared to be the most prominent sites of uptake, whereas less phage could be recovered from the heart ( Figure IIA in the online-only Data Supplement). 125 I-Streptavidinconjugated PP1 showed a similar biodistribution pattern ( Figure 3A) with, again, a substantial 2-fold increased accumulation by liver (Pϭ0.002), albeit that at an absolute level, hepatic 125 I-strep-bioPP1 uptake was less pronounced than that of PP1 phage. In keeping with this finding, serum clearance of 125 I-strep-PP1 was accelerated compared with that of its nontargeted counterpart and was accompanied by a significant reduction in kidney accumulation, suggestive of impaired renal excretion and preferential elimination by macrophage-rich organs ( Figure 3B) .
As SR-AI and CD36 were found to be the major scavenger receptors responsible for ligand uptake, 27 we intravenously injected strepPE-labeled PP1 into C57Bl/6 and SR-AI Ϫ/Ϫ / CD36 Ϫ/Ϫ mice. StrepPE-labeled biotin intravenously injected to C57Bl/6 mouse was used as a control. Immunofluorescent staining of macrophages ( Figure 3C , green) in liver and in spleen ( Figure IIB in the online-only Data Supplement) sections of C57Bl/6 mouse showed clear peptide accumulation and consistent colocalization (yellow overlay) of F4/80positive macrophages (green) with strepPE-PP1 (red) but not with biotin-conjugated PE signal. Importantly, PP1 targeted strepPE was barely detectable in macrophage-rich tissue of SR-AI Ϫ/Ϫ /CD36 Ϫ/Ϫ mice. With these data taken together, we demonstrated that PP1-induced spleen and liver uptake was attributable to macrophages and mediated by scavenger receptors.
PP1 Peptide Targets Atherosclerotic Aortic Artery Lesions in ApoE ؊/؊ Mice and Colocalizes With Intraplaque Macrophages
Because SR-AI was found to be considerably overexpressed in atherosclerotic lesions, we finally examined the capacity of PP1 peptide to target carriers to aortic artery lesions in aged ApoE Ϫ/Ϫ mice. Lesion size was expressed as relative Oil Red O-stained aortic area and amounted at least 20% of total aortic surface, reflecting the advanced stage of lesion development at 12 months. Importantly, although the plaque size in both treated groups did not differ (Figure 4A , right, and 4B, right), accumulation of radioactivity signal on autoradiograph of aortas after 125 I-strep-bioPP1 injection showed an increase of 84.12Ϯ7.0% compared with the autoradiograph signal after injection of 125 I-strep-biotin (Pϭ0.007; Figure 4A , left). These in vivo findings were recapitulated for PP1-conjugated fluorescent Qdot nanocrystals, indicating that PP1 targets SR-AI expressing macrophages, independent of the scaffold. For Qdots, we observed a similar 2-fold (93.65Ϯ28.78% increase; Pϭ0.013) increased accumulation in atherosclerotic lesions of age-matched ApoE Ϫ/Ϫ mice compared with untargeted control Qdots (Figure 4B, left) . Subsequent immunostaining of aortic sinus plaques for F4/80 ϩ intraplaque macrophages showed that 52.4Ϯ3.9% of all F4/80 ϩ macrophages were positive for PP1-conjugated Qdot fluorescence, which was substantially higher than its abundance in control Qdot-treated mice (6.3Ϯ3.9%; Pϭ0.002), as shown in Figure 4C and 4D. Of note, nonspecific control peptide (PP2) docked Qdots showed similarly low plaque uptake and macrophage colocalization than untargeted Qdots ( Figure III in the online-only Data Supplement). These data further strengthen the PP1-specific intraplaque macrophage uptake.
We conclude that PP1 facilitates the targeting of carriers to atherosclerotic lesions, probably by inducing macrophage SR-AI mediated uptake.
Discussion
Phage display of randomized peptide libraries has evolved into a very powerful strategy for the unbiased selection of peptide ligands that bind to diverse targets. 28 Here we have used phage display on the SR-AI receptor. We opted for a synthetic template, carrying the trimerized extracellular ligand binding domain, shown to adopt a configuration and ligand binding pattern very similar to that of SR-AI itself, 7 to bias the selection toward peptides that interact with the actual SR-AI binding pocket. Phage selection revealed SR-AI specific phage clones, with a shared 11-mer consensus motif in their insert. The C-terminus of both peptides differed, suggesting that the N-terminal part is instrumental in SR-AI binding. N-but not C-terminal biotinylated PP1 exhibited sharply reduced SR-AI binding after docking to streptavidin. Together with the truncation studies, these findings identify the N-terminal part of the peptide as minimal essential motif for SR-AI binding.
In keeping with the preference of trimeric SR-AI for oligomer substrates, 29 multimerization of PP1 on a streptavidin scaffold 30 resulted in an enhanced nanomolar potency for macrophage binding. Of note, M13 phage also displays its encoded peptides in a multimeric manner. The SR-AI binding phage not only bound avidly to the synthetic receptor but also to human THP-1 cells and, to a lesser extent, to murine RAW264.7 cells. The increased binding to THP-1 cells may be attributable to interspecies differences, as selection was done on bovine SR-AI, or to differences in SR-AI expression levels between these 2 cell lines, as has previously been reported for P-selectin phage display. 30 Background binding of the selected phage to SR-AI deficient COS-7 cells was very low, which is a clear advantage when aiming at targeted delivery and imaging approaches in vivo. Streptavidin immobilized PP1 is internalized by macrophages in an SR-AIdependent fashion in vitro. Selective SR-AI mediated uptake of PP1 targeted streptavidin could be confirmed in vivo, as in vivo kinetics of this carrier was altered in SR-AI Ϫ/Ϫ /
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Peptide Antagonist Selective for SR-AI CD36 Ϫ/Ϫ mice. Poly-I was able to displace phage binding to SR-AI, 31 but it does not bind to CD36, indicating that immobilized PP1 uptake is mainly SR-AI dependent. Interestingly, a protein BLAST search for short, nearly exact matches of PP1 revealed a high homology of the N-terminal heptapeptide LSLERFL to viruses such as human cytomegalovirus and human immunodeficiency virus ( Table I in the online-only Data Supplement), both implicated in atherosclerosis. 32 As SR-AI was found to interact with Gram-positive bacteria, 10 it is tempting to speculate that macrophage uptake of these pathogens may be at least partly SR-AI mediated and proceed through the LSLERFL motif also present on Gram-positive bacteria.
SR-AI-selective binding phage and streptavidin-conjugated PP1 exhibited a similar biodistribution pattern in vivo with liver being the major site of elimination, indicating that liver macrophages account for the bulk of SR-A ligand clearance. 31 Differences in accumulation in heart, spleen and lung likely reflect intrinsic differences in M13 phage versus streptavidin clearance. It should be noted that the relative organ uptake of 125 I-streptavidin may in fact be considerably underestimated because of the very effective breakdown and excretion of iodinated substrates by SR-AI.
Although in recent years molecular imaging of inflammatory atherosclerotic plaques has drawn considerable interest, it remains a major challenge. 33 Macrophages are not only instrumental in onset and progression of atherosclerotic plaque development, but their density in plaque is also reflective of plaque vulnerability. 34 Numerous research groups have embraced this leukocyte subset as ultimate target for molecular imaging of inflammatory, vulnerable plaques (detailed review see 35 ) , often using the scavenger receptors as route of entry. 36 Most macromolecular SR-AI ligands display couple immunogenicity to a low penetration capacity. Furthermore, targeted delivery with oligodeoxyguanosine lacked the desired specificity and elicited Toll-like receptor dependent immune response. 31 Synthetic PP1 may contrast favorably to these tools in this regard. It shows a similar to higher in vivo accumulation ratio compared with alternatives, such as macrophage-targeted immunomicelles, 17 MDA2, 18 oxidized low-density lipoprotein targeted 18 and tyrosine polyethylene glycol micelles 37 and high-density lipoprotein-based contrast agent 38 (Table II in the online-only Data Supplement). Although at least equally effective and synthetically flexible, peptide based homing vehicles may perform better in terms of receptor specificity (polyethylene glycol micelles, high-density lipoprotein contrast agents), immunogenicity (MDA2 micelles, synthetic high-density lipoprotein), and cell activation (liposomes). PP1-equipped contrast agents (positron emission tomography or magnetic resonance imaging) may thus represent effective screening tools to detect macrophage-rich atherosclerotic lesions in the patient at risk, and, in a more general sense, inflammatory foci, precisely mapping location and extent of inflammation.
A few limitations need to be acknowledged regarding the present study. First, short circulation time and dimension constraints imposed by the mouse model itself may have led to suboptimal signal to noise ratios. Conceivably, larger animal models will allow better spatial resolution and higher signals. Second, the choice of the imaging platforms, quantum dots, and streptavidin-based protein scaffolds is not representative of the clinically used imaging tools. Although, our consistent data suggest that PP1's targeting potential is independent of the actual substrate, conclusive studies using accepted contrast agents or probes such as iron oxide, Gd, or radioactive metal ions are needed. A third focus of attention are undesired side effects in the plaque 39 on binding and uptake of particles via SR-AI, although our findings did not point in that direction.
In conclusion, a novel phage display strategy based on biopanning on synthetic ligand binding peptide of SR-AI, was successfully applied for the design of PP1, a selective SR-AI antagonist. PP1 effectively targeted SR-AI expressing cells in vitro and in vivo. Moreover, we demonstrated that PP1 is able to redirect imaging modalities to atherosclerotic lesions in vivo. Given the preference of PP1 for human SR-AI, the plaque homing capacity of this peptide in humans may even be superior to that in mice. This lead may thus not only form the promising starting point for the design of even more potent SR-AI inhibitors but also prove useful in the development of imaging and targeting strategies aimed at macrophage-enriched sites of inflammation, such as the atherosclerotic plaque.
